NBIX vs ONCO · P/E 45, rev $1.77B vs P/E 0.0, rev $815.4K
Neurocrine Biosciences Inc (NBIX) versus Onconetix Inc (ONCO) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Onconetix Inc (ONCO) is a biotechnology company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported ONCO revenue for 2025-12-31 was $815.4K. Net income was -$14.0M. Revenue was down 67.7% from 2024-12-31 to 2025-12-31. ONCO currently screens at market cap $3.7M and trailing P/E 0.0.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. ONCO currently screens at market cap $3.7M and trailing P/E 0.0.
Not investment advice. Open the NBIX and ONCO stock pages for the full models.
Not investment advice.